[GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients].

MLA

Marques, Ana Rita Forte, et al. “[GLP-1 Receptor Agonists versus SGLT-2 Inhibitors in Obese Type 2 Diabetes Patients].” Revue Medicale Suisse, vol. 11, no. 477, June 2015, p. 1227. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=26211282&authtype=sso&custid=ns315887.

APA

Marques, A. R. F., Jaafar, J., de Kalbermatten, B., & Philippe, J. (2015). [GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients]. Revue Medicale Suisse, 11(477), 1227.

Chicago

Marques, Ana Rita Forte, Jaafar Jaafar, Bénédicte de Kalbermatten, and Jacques Philippe. 2015. “[GLP-1 Receptor Agonists versus SGLT-2 Inhibitors in Obese Type 2 Diabetes Patients].” Revue Medicale Suisse 11 (477): 1227. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=26211282&authtype=sso&custid=ns315887.